NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

AGEN

Agenus Inc

Jul 01 • 04:00PM ET

4.84

Dollar change +0.27
Percentage change 5.91	%

Healthcare • Biotechnology • USA • NASD

Peers: BMY MRK PFE GILD JNJ AMGN VRTX REGN BIIB LLY

| Held by: VTI VXF VTWO IWM IWC VHT IWN VTWV CHNA MSSM

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-8.68	Insider Own	3.86%	Shs Outstand	26.56M	Perf Week	-3.20%
Market Cap	132.70M	Forward P/E	4.82	EPS next Y	1.00	Insider Trans	0.00%	Shs Float	26.36M	Perf Month	41.11%
Enterprise Value	550.60M	PEG	-	EPS next Q	1.03	Inst Own	32.02%	Short Float	12.20%	Perf Quarter	221.59%
Income	-190.81M	P/S	1.33	EPS this Y	74.98%	Inst Trans	12.25%	Short Ratio	2.94	Perf Half Y	72.24%
Sales	99.52M	P/B	-	EPS next Y	137.92%	ROA	-83.45%	Short Interest	3.21M	Perf YTD	76.64%
Book/sh	-12.87	P/C	7.18	EPS next 5Y	38.34%	ROE	-	52W High	18.74 -74.17%	Perf Year	-65.72%
Cash/sh	0.67	P/FCF	-	EPS past 3/5Y	-71.25% 7.90%	ROIC	-	52W Low	1.38 250.72%	Perf 3Y	-87.02%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-29.53% -7.17%	Gross Margin	86.25%	Volatility	9.42% 11.38%	Perf 5Y	-94.10%
Dividend TTM	-	EV/Sales	5.53	EPS Y/Y TTM	31.19%	Oper. Margin	-105.36%	ATR (14)	0.47	Perf 10Y	-97.13%
Dividend Ex-Date	-	Quick Ratio	0.11	Sales Y/Y TTM	-38.34%	Profit Margin	-191.72%	RSI (14)	54.62	Recom	2.20
Dividend Gr. 3/5Y	- -	Current Ratio	0.11	EPS Q/Q	65.97%	SMA20	-3.51%	Beta	1.51	Target Price	11.50
Payout	-	Debt/Eq	-	Sales Q/Q	-14.07%	SMA50	22.64%	Rel Volume	1.00	Prev Close	4.57
Employees	316	LT Debt/Eq	-	Earnings	May 12 BMO	SMA200	37.69%	Avg Volume	1.09M	Price	4.84
IPO	Feb 04, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	37.73% 9.48%	Trades		Volume	1,087,878	Change	5.91%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-04-25	Upgrade	H.C. Wainwright	Neutral → Buy	$25
Jul-19-24	Downgrade	Robert W. Baird	Outperform → Neutral	$35 → $8
Jul-18-24	Downgrade	William Blair	Outperform → Mkt Perform
Jul-18-24	Downgrade	H.C. Wainwright	Buy → Neutral	$9
Jun-06-23	Initiated	Robert W. Baird	Outperform	$8
Jun-06-23	Initiated	Robert W. Baird	Outperform	$60 → $80
Feb-28-23	Resumed	H.C. Wainwright	Buy	$8
Sep-28-22	Initiated	SMBC Nikko	Outperform	$5
Dec-16-21	Initiated	H.C. Wainwright	Buy	$12
Nov-19-19	Resumed	B. Riley FBR	Buy	$6
Apr-22-19	Initiated	B. Riley FBR	Buy
Oct-28-16	Downgrade	H.C. Wainwright	Buy → Neutral	$10 → $5
Oct-27-16	Reiterated	Maxim Group	Buy
Mar-11-16	Upgrade	Maxim Group	Hold → Buy	$7
Dec-16-15	Initiated	Jefferies	Buy
Oct-27-15	Downgrade	Maxim Group	Buy → Hold
Jul-27-15	Reiterated	MLV & Co	Buy	$9 → $11
Jun-11-15	Initiated	Oppenheimer	Outperform	$14
Jan-12-15	Reiterated	Maxim Group	Buy	$10 → $11
Jan-09-15	Reiterated	MLV & Co	Buy	$6 → $9

Show Previous Ratings

Today 10:50AM	Biogen Begins Phase III Felzartamab Study for Third Kidney Disease (Zacks) +5.91%
09:17AM	Moderna Stock Gains on Encouraging Flu Vaccine Data (Zacks)
Jun-30-25 11:40AM	RARE's GTX-102 Gets FDA's Breakthrough Status for Angelman Syndrome (Zacks)
Jun-27-25 09:40AM	Are Medical Stocks Lagging CVS Health (CVS) This Year? (Zacks)
Jun-25-25 11:17AM	KRYS Up 4% on Initiating Dosing in Rare Eye Disease Phase III Study (Zacks)
11:06AM	Loading…
11:06AM	Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU (Zacks)
10:02AM	Sanofi's Experimental Transplant Rejection Drug Gets FDA Orphan Tag (Zacks)
Jun-24-25 11:58AM	CHMP Backs NVO's Ozempic EU Label Update for Cardiovascular Indication (Zacks)
09:04AM	FDA Grants Label Expansion to AstraZeneca's Datroway in Lung Cancer (Zacks)
Jun-23-25 09:15AM	J&J's Drugs Get CHMP Recommendations for Blood Cancer Indications (Zacks)
Jun-19-25 09:55AM	After Golden Cross, Agenus (AGEN)'s Technical Outlook is Bright (Zacks)
Jun-17-25 12:02PM	Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy (Zacks) -7.00%
10:30AM	AbbVie's Venclexta Misses Goal in Myelodysplastic Syndromes Study (Zacks)
07:30AM	Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology (Business Wire)
Jun-16-25 03:01PM	Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock (Insider Monkey) +9.36%
08:45AM	Loading…
08:45AM	SRPT Plummets on Second Patient Death After DMD Gene Therapy Infusion (Zacks)
Jun-10-25 01:30PM	Agenus Announces Virtual Annual Shareholders Meeting (Business Wire)
Jun-05-25 10:03AM	FDA Grants Platform Technology Tag to Sarepta's Gene Therapy Vector (Zacks) -8.35%
Jun-04-25 09:55AM	Wall Street Analysts Believe Agenus (AGEN) Could Rally 26.6%: Here's is How to Trade (Zacks) +12.60%
07:33AM	Agenus and Zydus sign agreements for botensilimab and balstilimab (Pharmaceutical Technology)
Jun-03-25 07:00AM	Agenus and Zydus Lifesciences Enter $141M Strategic Collaboration to Advance BOT/BAL, Expand Zydus Biologics Manufacturing in the US (Business Wire) +21.07%
May-30-25 07:30AM	Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer (Business Wire) +7.19%
May-29-25 11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks) +5.96%
11:08AM	U.S. Govt. Cancels $766M Funding Contract for Moderna's Bird Flu Shot (Zacks)
May-19-25 09:06AM	BioMarin Offers to Buy Inozyme for $270M to Boost Enzyme Therapy Biz (Zacks) +8.91%
08:50AM	Despite Fast-paced Momentum, Agenus (AGEN) Is Still a Bargain Stock (Zacks)
May-16-25 10:45AM	Agenus says expanded MSS mCRC cohort data to be presented at ESMO GI (TipRanks)
May-15-25 10:40AM	Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025 (Business Wire)
08:42AM	AbbVie Secures FDA Nod for New ADC Drug Emrelis in Lung Cancer (Zacks)
May-14-25 06:29AM	Allogene's Q1 Earnings In Line With Estimates, Sales Nil (Zacks)
03:03AM	Loading…
May-13-25 03:03AM	Agenus Inc (AGEN) Q1 2025 Earnings Call Highlights: Strategic Moves and Financial Challenges (GuruFocus.com)
02:57AM	Q1 2025 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
May-12-25 08:50AM	Agenus (AGEN) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +20.27%
07:47AM	Agenus: Q1 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Q1 2025 Financial Results and Key Business Updates (Business Wire)
07:20AM	Renowned GI Oncology Leader Dr. Richard Goldberg Joins Agenus as Chief Development Officer (Business Wire)
May-09-25 09:47AM	Agenus Inc (AGEN) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
09:40AM	Is ANI Pharmaceuticals (ANIP) Outperforming Other Medical Stocks This Year? (Zacks)
May-08-25 09:25AM	MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates (Zacks)
May-07-25 06:15PM	Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Lags Revenue Estimates (Zacks)
12:42PM	Waters Q1 Earnings Surpass Estimates, Revenue Rise Y/Y (Zacks)
May-05-25 05:15PM	Vertex Pharmaceuticals (VRTX) Misses Q1 Earnings and Revenue Estimates (Zacks)
Apr-29-25 10:01AM	Agenus (AGEN) May Report Negative Earnings: Know the Trend Ahead of Q1 Release (Zacks)
07:30AM	Agenus to Provide Corporate Update and First Quarter 2025 Financial Report (Business Wire)
Apr-28-25 03:30PM	Agenus BOT/BAL Neoadjuvant Pan-Cancer Data from the NEOASIS Study Presented in an Oral Session at AACR (Business Wire) +16.30%
Apr-25-25 01:05PM	Agenus' BOT/BAL Data in Pretreated Liver Cancer Presented at AACR 2025 (Business Wire)
Apr-23-25 12:05PM	Agenus Announces Botensilimab and Balstilimab Presentations at ASCO 2025 (Business Wire)
09:40AM	Are Medical Stocks Lagging ANI Pharmaceuticals (ANIP) This Year? (Zacks)
Apr-10-25 08:52AM	Abbott's Q1 Earnings Coming Up, Medical Devices Arm in Focus (Zacks) -6.09%
Mar-25-25 04:40PM	Agenus to Present New BOT/BAL Data in Two Presentations at AACR 2025 (Business Wire)
09:55AM	Here's Why Agenus (AGEN) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-19-25 07:30AM	Agenus Unveils Colorectal Cancer Survey Findings, Highlighting the Urgent Need for Treatment Innovation (Business Wire)
Mar-12-25 03:03AM	Agenus Inc (AGEN) Q4 2024 Earnings Call Highlights: Strategic Moves Amid Financial Challenges (GuruFocus.com) -9.02%
01:35AM	Q4 2024 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-11-25 11:45AM	Agenus (AGEN) Q4 2024 Earnings Call Transcript (Motley Fool)
08:40AM	Agenus (AGEN) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
07:43AM	Agenus: Q4 Earnings Snapshot (Associated Press Finance)
07:30AM	Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program (Business Wire)
Feb-26-25 04:48PM	Agenus Reports Impact of Key Immuno-Oncology Data Presented at Leading Medical Conferences and Peer-Reviewed Publications (Business Wire) -8.63%
Feb-25-25 02:30PM	Agenus to Participate in B. Riley Securities Precision Oncology & Radiopharma Investor Conference (Business Wire)
08:26AM	Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2024 Financial Report (Business Wire)
Feb-24-25 08:33AM	Agenus Presents New Botensilimab/Balstilimab Data in Gastric Cancer at AACR IO Annual Meeting (Business Wire)
Feb-23-25 07:38PM	CORRECTING and REPLACING Agenus' BOT/BAL Selected for Two Presentations at Upcoming AACR IO Annual Meeting (Business Wire)
Feb-21-25 09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-06-25 08:50AM	Agenus (AGEN) Is Attractively Priced Despite Fast-paced Momentum (Zacks)
Feb-05-25 09:40AM	Are Medical Stocks Lagging Agenus (AGEN) This Year? (Zacks) +11.43%
Jan-29-25 12:37PM	Agenus Announces Publication in the Journal of Clinical Oncology Highlighting Data from Botensilimab Plus Balstilimab in Relapsed/Refractory Metastatic Sarcomas (Business Wire)
Jan-22-25 02:48PM	Agenus Presents Data at ASCO GI Demonstrating Impact of BOT/BAL in Colorectal Cancer Across Neoadjuvant and Advanced Disease (Business Wire)
Jan-20-25 12:00PM	What Makes Agenus (AGEN) a New Buy Stock (Zacks)
09:40AM	Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Dec-18-24 07:30AM	Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers (Business Wire) -8.12%
Dec-06-24 06:07AM	AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B (BioPharma Dive) +14.01%
Dec-05-24 07:30AM	Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs (Business Wire) -8.45%
Nov-27-24 10:20AM	Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development (Benzinga)
08:15AM	Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment (Business Wire)
Nov-19-24 09:35AM	Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-18-24 09:35AM	Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-15-24 09:35AM	Down -39.39% in 4 Weeks, Here's Why Agenus (AGEN) Looks Ripe for a Turnaround (Zacks)
Nov-13-24 02:18AM	Q3 2024 Agenus Inc Earnings Call (Thomson Reuters StreetEvents)
02:08AM	Agenus Inc (AGEN) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges While ... (GuruFocus.com)
Nov-12-24 12:15PM	Agenus (AGEN) Q3 2024 Earnings Call Transcript (Motley Fool) -20.38%
08:20AM	Agenus (AGEN) Reports Q3 Loss, Lags Revenue Estimates (Zacks)
07:19AM	Agenus: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	Agenus Reports Third Quarter 2024 Financial Results and Strategic Advancements in BOT/BAL Development (Business Wire)
Nov-11-24 07:24AM	Earnings To Watch: Agenus Inc (AGEN) Reports Q3 2024 Result (GuruFocus.com)
Nov-07-24 10:00AM	Agenus to Present Compelling Data on Botensilimab and AGEN1721 at SITC 2024 (Business Wire) -6.87%
07:00AM	Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance (Business Wire)
Nov-05-24 07:30AM	Agenus to Provide Third Quarter 2024 Financial Report and Corporate Update (Business Wire)
Nov-01-24 05:45AM	Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Oct-29-24 05:45AM	Investors in Agenus Inc. Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Sep-19-24 01:31PM	Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights AGEN (GlobeNewswire)
Sep-17-24 05:45AM	Agenus Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights - AGEN (PR Newswire)
Sep-16-24 12:51PM	Agenus Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky Before November 5, 2024 to Discuss Your Rights AGEN (GlobeNewswire)
Sep-13-24 10:00AM	Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024 (Business Wire) +5.56%
Sep-09-24 07:30AM	Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024 (Business Wire)
Sep-03-24 07:30AM	Agenus to Participate in September Investor Conferences (Business Wire)
Aug-08-24 04:15PM	Agenus (AGEN) Q2 2024 Earnings Call Transcript (Motley Fool)
08:10AM	Agenus (AGEN) Reports Q2 Loss, Lags Revenue Estimates (Zacks)
07:08AM	Agenus: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	Agenus Reports Second Quarter 2024 Operational and Financial Results (Business Wire)

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

AGEN

Agenus Inc

Upgrade your FINVIZ experience